Aerie Pharmaceuticals’ (AERI) “Buy” Rating Reiterated at Mizuho

Mizuho reiterated their buy rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research report sent to investors on Wednesday, October 25th. The firm currently has a $70.00 price target on the stock.

Other analysts have also recently issued reports about the company. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 16th. HC Wainwright set a $69.00 price target on Aerie Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 2nd. Stifel Nicolaus reaffirmed a buy rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Needham & Company LLC reaffirmed a buy rating and issued a $65.00 price target on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Finally, Cowen and Company reaffirmed a buy rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $70.93.



Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded up $0.25 during mid-day trading on Wednesday, hitting $62.00. The stock had a trading volume of 324,800 shares, compared to its average volume of 512,286. The company has a debt-to-equity ratio of 0.67, a current ratio of 22.44 and a quick ratio of 22.45. Aerie Pharmaceuticals has a one year low of $35.20 and a one year high of $66.25.

COPYRIGHT VIOLATION WARNING: “Aerie Pharmaceuticals’ (AERI) “Buy” Rating Reiterated at Mizuho” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://ledgergazette.com/2017/11/13/mizuho-reaffirms-buy-rating-for-aerie-pharmaceuticals-inc-aeri.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in shares of Aerie Pharmaceuticals by 22.1% during the 1st quarter. Wells Fargo & Company MN now owns 26,273 shares of the company’s stock worth $1,191,000 after acquiring an additional 4,758 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Aerie Pharmaceuticals by 97.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 12,430 shares of the company’s stock worth $564,000 after acquiring an additional 6,130 shares in the last quarter. Karp Capital Management Corp bought a new position in shares of Aerie Pharmaceuticals during the 1st quarter worth approximately $213,000. Parametric Portfolio Associates LLC grew its stake in shares of Aerie Pharmaceuticals by 5.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock worth $3,102,000 after acquiring an additional 3,739 shares in the last quarter. Finally, Ameritas Investment Partners Inc. bought a new position in shares of Aerie Pharmaceuticals during the 1st quarter worth approximately $108,000. 94.67% of the stock is owned by institutional investors and hedge funds.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply